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of subcortical structures in frontotemporal
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Whilst initial anatomical studies of frontotemporal dementia focussed on cortical involvement, the relevance of subcortical struc-
tures to the pathophysiology of frontotemporal dementia has been increasingly recognized over recent years. Key structures affected
include the caudate, putamen, nucleus accumbens, and globus pallidus within the basal ganglia, the hippocampus and amygdala
within the medial temporal lobe, the basal forebrain, and the diencephalon structures of the thalamus, hypothalamus and habe-
nula. At the most posterior aspect of the brain, focal involvement of brainstem and cerebellum has recently also been shown in cer-
tain subtypes of frontotemporal dementia. Many of the neuroimaging studies on subcortical structures in frontotemporal dementia
have been performed in clinically defined sporadic cases. However, investigations of genetically- and pathologically-confirmed
forms of frontotemporal dementia are increasingly common and provide molecular specificity to the changes observed.
Furthermore, detailed analyses of sub-nuclei and subregions within each subcortical structure are being added to the literature,
allowing refinement of the patterns of subcortical involvement. This review focuses on the existing literature on structural imaging
and neuropathological studies of subcortical anatomy across the spectrum of frontotemporal dementia, along with investigations
of brain–behaviour correlates that examine the cognitive sequelae of specific subcortical involvement: it aims to ‘look beneath the
surface’ and summarize the patterns of subcortical involvement have been described in frontotemporal dementia.
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Introduction
Frontotemporal dementia (FTD) is a common cause of
early onset dementia, approximately equal in frequency
to Alzheimer’s disease in people under the age of 65. It is
clinically heterogeneous with symptoms, including behav-
ioural, language, cognitive and motor deficits.
Behavioural variant FTD (bvFTD) is the most common
presentation, with impaired social conduct and personal-
ity changes,1 whilst less frequently, people present with
progressive decline in speech and language functions [pri-
mary progressive aphasia (PPA)], of which there are mul-
tiple variants: semantic variant (svPPA), non-fluent
variant (nfvPPA) and logopenic variant (lvPPA).2 People
on this spectrum can also develop motor features consist-
ent with either amyotrophic lateral sclerosis (ALS) or par-
kinsonism [including progressive supranuclear palsy
(PSP), or corticobasal syndrome (CBS)].3 At present the
only known risk factors for FTD are age and genetics:
about a third of cases are due to an autosomal dominant
mutation in microtubule-associated protein tau (MAPT),
progranulin (GRN) or chromosome 9 open reading frame
72 (C9orf72) genes.4 Pathologically, three major groups
are described according to the main abnormal protein
seen in neuronal or glial inclusions— tau, TAR DNA-
binding protein 43 (TDP-43) and fused-in-sarcoma
(FUS)5,6— with multiple subtypes seen within each main
group.
Anatomically, FTD has traditionally been characterized
as a cortical dementia with atrophy predominantly of the
frontal and temporal lobes, hence its name. However,
imaging and neuropathological studies have identified not
only other cortical areas (including the insula and anter-
ior cingulate) but also subcortical structures as key areas
of FTD-related degeneration,7 even at the very early
stages of the disorder8–16 and presymptomatic phases.17
Behavioural studies have highlighted the relevance of
subcortical structures in the development of the typical
symptoms of FTD. Subcortical structures contribute to
functional and structural brain networks that are affected
in FTD. For example, a reward network related to the
limbic system18 regulates appropriate behaviour for a
given context by the evaluation of motivational and emo-
tional content of the stimuli. Abnormal functioning of
this circuit in bvFTD leads to abnormal responses to
rewards (including food, sex and substance use).19
This review aims to provide a comprehensive overview
of the involvement of subcortical structures in the FTD
spectrum (Fig. 1), identified by structural magnetic reson-
ance (MR) imaging, with neuropathological corroboration
of the imaging data.
For each of the structures, we first describe their anat-
omy and structural connections (‘Anatomy’), and then re-
port the MRI studies that have investigated changes
in vivo in their volume or morphology within the genetic,
clinical and pathological forms of FTD (‘Neuroimaging’).
This is followed by the description of which studies have
reported abnormal findings at post mortem examination
(‘Neuropathology’), and then finally, in the
‘Symptomatology’ section, we discuss how such structural
changes contribute to the behavioural and cognitive defi-
cits seen in people with FTD.
Basal ganglia
Striatum
Anatomy. The striatum consists of dorsal and ventral
regions. The dorsal striatum comprises the caudate and
putamen and is primarily associated with sensorimotor
functions, whilst the ventral striatum includes the nucleus
accumbens and is a component of the limbic circuit,
which modulates behaviour and memory.20
The striatum has multiple parallel connections with the
prefrontal cortex, anterior cingulate cortex, orbitofrontal
cortex, insula, inferior and middle temporal gyrus, and
thalamus.21 Anatomical and physiological studies have
identified functionally distinct but anatomically analogous
cortico-striato-pallido-thalamic-cortical circuits. These
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process information in parallel and have separate connec-
tions and functions.20,21 In the motor circuit and oculo-
motor circuit, the putamen and the caudate receive input
from the primary motor, somatosensory, premotor, sup-
plementary motor and posterior parietal cortex, together
with the frontal eye fields. They then send their output
to the supplementary motor cortex and frontal eye fields,
via the globus pallidus (internal segment), substantia
nigra (pars reticulata) and thalamus (ventrolateral and
ventral anterior and mediodorsal nuclei).20,22 The other
three circuits originate from and end in the frontal cor-
tex, but they have different pathways and have different
roles in cognition, emotion and motivation.21 The dorso-
lateral prefrontal circuit is associated with executive func-
tion. The dorsolateral prefrontal cortex, together with the
posterior parietal and premotor cortex, is connected to
the dorsolateral head of the caudate, to the globus pal-
lidus and substantia nigra, and to the thalamus (ventral
anterior and mediodorsal nuclei). The lateral orbito-
frontal circuit regulates inhibition and impulses. It is
connected to the ventral anterior and mediodorsal nuclei
of the thalamus via the ventromedial head of the caud-
ate (which also receives inputs from the superior tem-
poral gyrus, inferior temporal gyrus and anterior
cingulate) and the globus pallidus and substantia nigra.
In the anterior cingulate circuit, the nucleus accumbens
and ventromedial caudate receive input from the anter-
ior cingulate, and limbic and paralimbic regions (hippo-
campus, entorhinal cortex, insula, amygdala, superior
and inferior temporal gyrus and temporal pole) with
output via the globus pallidus and substantia nigra to
the mediodorsal thalamus. This is the crucial pathway
controlling motivation.20,21
The nucleus accumbens additionally projects to the
basal forebrain and the lateral preoptic area and lateral
hypothalamus.23 This nucleus can be further divided into
a ‘shell’ and ‘core’, at least in preclinical models: the shell
is connected to the medio-temporal regions (hippocampal
cornu ammonis 1—CA1, CA3 and subiculum, entorhinal
cortex, basolateral amygdaloid nucleus), the paraventricu-
lar thalamic nucleus and the caudal brainstem, while the
functionally distinct core is connected to the dorsomedial
prefrontal cortex, anterior cingulate, insula, parahippo-
campal cortex, midline and intralaminar thalamic nuclei,
and the basolateral amygdaloid nucleus.
Neuroimaging. Clinically, the caudate is affected in both
behavioural and language phenotypes of FTD. Compared
to controls, the caudate is 11–25% smaller in bvFTD,
21% smaller in nfvPPA (worse on the left) and 8%
smaller in svPPA (worse on the left).7,14,16,24–29 Similarly,
the putamen is affected across all clinical syndromes being
7–28% smaller in bvFTD, 13% smaller in nfvPPA (worse
on the left) and 11–21% smaller in svPPA (worse on the
left) than controls.7,14,16,26,29,30 The subregions of the puta-
men may be equally affected by each syndrome.25
Among the genetic forms of FTD, GRN mutation
carriers in particular have shown involvement of the
dorsal striatum.17,31 Patients with GRN mutations show
especially severe atrophy in the caudate (56% reduction
versus controls), while putamen atrophy is similar to
sporadic cases (27% reduction versus controls).32 A re-
cent study in a large cohort of mutation carriers has
found that the GRN group showed smaller volumes in
the putamen (17% difference versus controls) and caud-
ate (5%) only when they were fully symptomatic, but not
at earlier stages.33 In the same study, C9orf72 expansion
Figure 1 Subcortical structures involved in frontotemporal dementia. Structures are grouped and coloured based on their location and
anatomical organization. The basal ganglia include the striatum (nucleus accumbens, caudate and putamen), the globus pallidus, substantia nigra
and subthalamic nucleus. The amygdala and hippocampus are located in the medial temporal lobe, while the thalamus, hypothalamus and
habenula are part of the diencephalon. Below the cerebrum, lie the cerebellum and brainstem (midbrain, pons and medulla oblongata).
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carriers were found to have smaller putaminal volumes in
asymptomatic and prodromal stages (1–6%) through to
fully symptomatic stages (17%), while MAPT mutation
carriers were only abnormal at a fully symptomatic stage
(17%).
Including pathologically confirmed cases, an early in-
vestigation showed no volumetric differences in any brain
region comparing tau and TDP-43 cases.34 However, in a
more detailed study looking at pathological subtypes the
group of patients with FUS pathology showed the most
severe degree of caudate atrophy in comparison with con-
trols (34% difference from controls),15 aligning with the
evidence from multiple prior case series.35,36 Although
with lesser severity, caudate atrophy was also seen across
multiple pathologies e.g. Pick’s disease (23% difference
from controls), corticobasal degeneration (CBD) (15%),
TDP-43 type A (14%), frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17)
(13%) and TDP-43 type C (11%). Furthermore, in this
study, atrophy in the putamen was more marked than in
the caudate in most groups (apart from FUS): Pick’s
disease (38% difference from controls), FUS (33%),
FTDP-17 (25%), CBD (24%), TDP-43 type A (25%) and
TDP-43 type C (19%).
The ventral striatum, in the form of the nucleus accum-
bens, has been less studied than the dorsal region.
However, atrophy in this region occurs in both bvFTD
and svPPA, with volumes from 30% to 50% smaller
than controls.7,14,26,28,29 Among the genetic forms, only
symptomatic MAPT mutation carriers showed smaller
volumes in the nucleus accumbens (11%).33 There may
be asymmetry in the progression of atrophy. For ex-
ample, in patients with TDP-43 type C pathology, atro-
phy of the left nucleus accumbens precedes the right.37
Current studies have not addressed whether the core or
shell of the accumbens is more affected in different forms
of FTD.
Pathology. Several studies have characterized post mortem
striatal volume loss38 and histopathology.39,40 Consistent
with neuroimaging evidence, the most severe striatal atro-
phy has been seen in cases with FUS pathology,41 espe-
cially in the caudate.
Studies focussing on genetic forms of FTD confirm the
abnormalities of the basal ganglia, with prevalent involve-
ment of the caudate in cases with GRN mutations,41 and
severe neuronal loss and gliosis of the striatum along
with TDP-43 inclusions.42 In FTDP-17, macroscopic atro-
phy is detectable at the intermediate stage in the caudate
nucleus, whilst caudate and putaminal volume loss is
evident in advanced illness.43
Patients with both tau and TDP-43 pathology show
neuron loss, astrogliosis and focal microvacuolation in
the ventral striatum, accompanied by tau or TDP-43
immunoreactive neuronal cytoplasmic inclusions and
dystrophic neurites. In particular, svPPA patients with
TDP-43 type C show abundant and focal neuronal
cytoplasmic inclusions in the accumbens.26 In these
patients with frontotemporal lobar degeneration (FTLD),
the greatest amount of TDP-43 pathology is in the ven-
tral striatum, followed by the putamen and the dorsal
caudate.44
Symptomatology. Striatal degeneration determines diverse
symptoms of FTD, directly and indirectly via the striatal
projections to other regions. For example, striatal lesions
are associated with decreased globus pallidus inhibition
which leads to enhanced thalamic inhibition and reduced
cortical activation. Striatal atrophy is therefore associated
with disinhibition,7,45 binge eating19,46 and poor memory
recall.47 Loss of the striatum innervation and atrophy can
also result in akinesia and parkinsonism, which are
reported in over half of the patients with FTD48 and a
third of patients with right-temporal variant FTD.39
Parkinsonism has also been observed in nfvPPA, and
linked to the progressive striatal atrophy and dopamine
depletion in the putamen and caudate that characterize
this syndrome.49
The role of the dorsal striatum and its connectivity
with the frontal lobe is mirrored between FTD and other
lesions to the dorsal fronto-striatal network, with execu-
tive dysfunction and behavioural impairment in FTD. In
particular, dysexecutive syndromes are also associated
with atrophy of the regions connected to the dorsolateral
prefrontal cortex (e.g. antero-dorsal head of the caudate).
On the other hand, neuropathology in the ventromedial
head of the caudate and its connections to the orbitofron-
tal cortex leads to loss of socially appropriate behaviours,
abnormal reward-seeking and disinhibited or impulsive
behaviours.19 The nucleus accumbens has a key role in
the representation of rewards associated with response
options to stimuli, and it represents the outcome value of
actions, weighting short and long-term consequences.
Damage alters the representation of risks, for immediate
versus delayed gratification.23 This explains why degener-
ation of this nucleus leads to impulsivity and disinhib-
ition, typical of bvFTD.50 In bvFTD and svPPA, this may
present with disinhibited sexual behaviours, repetitive or
compulsive behaviours, abnormal eating behaviour and
substance abuse.26,51,52 Degeneration of the nucleus
accumbens or ventromedial caudate can also lead to ap-
athy, as observed in all FTD syndromes, as a result of
reduced motivation.21,53–55 Moreover, there is an associ-
ation between reduced putamen volumes and severity of
behavioural symptoms in FTD.14,19,56 Laterality effects
may also be present but are less consistently reported.
For example, overeating and sweet preference in bvFTD
patients has been associated with selective right striatal
degeneration.19,46
In genetic FTD, impairment of negative, as well as
positive, outcome representations may account for the
association of striatal atrophy with abnormal pain per-
ception in C9orf72-associated FTD.57 Abnormal re-
inforcement learning as a result of striatal atrophy may
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also underpin psychotic symptoms, which is particularly
common in C9orf72-associated FTD.58 In GRN- and
MAPT-associated FTD, striatal atrophy is related to
impaired social cognition.59
Globus pallidus
Anatomy. Another important nucleus of the basal ganglia
is the globus pallidus, which has been closely associated
with motor symptoms and signs, but which also mediate
cognitive functions.60 As part of the ‘motor’ circuit, the
ventrolateral globus pallidus receives input from the puta-
men and projects to the ventrolateral thalamic nucleus,
which is linked to the supplementary motor cortex. The
dorsomedial globus pallidus is connected to the anterior
caudate and ventral anterior thalamic nucleus, while the
lateral pallidus is connected to the dorsolateral caudate.
The latter projects indirectly to the dorsolateral prefrontal
cortex, creating a circuit linked to executive function and
behavioural control.20 Ventral and antero-lateral regions
of the pallidus are also connected to the nucleus accum-
bens, as part of the limbic system, mediating reward and
thereby impulsive or inappropriate actions in FTD.
Neuroimaging. In bvFTD, the globus pallidus has been
shown to be approximately 10% smaller than con-
trols.7,26,28 The only study looking at genetic FTD across
disease stages has found that fully symptomatic MAPT
and GRN mutation carriers showed smaller volumes
compared to controls (12–14%), while C9orf72 expan-
sion carriers showed reduced volumes (6%) even at a
prodromal stage, reaching 16% volumetric difference
when fully symptomatic.33 The relatively small size of the
pallidus, and poor contrast to noise in many standard
volumetric MRI sequences, means that its importance to
FTD symptomatology may have been under-recognised
from previous imaging studies.
Pathology. In a study on pathologically confirmed cases of
FTLD, only few TDP-43 inclusions were found in the
globus pallidus and ventral pallidus, compared to other
basal ganglia structures.44 FUS-positive lesions were
found in the globus pallidus in bvFTD with neuronal
intermediate filament inclusion disease pathology.61 These
were less frequent in bvFTD cases with atypical FTLD
with ubiquitinated inclusions. A case study of a patient
with bvFTD and TDP-43 type C revealed severe neuronal
loss, gliosis and TDP-43 inclusions in the pallidus as for
other regions of the basal ganglia.62 Cases with bvFTD
and parkinsonism due to a mutation in MAPT showed
tau positive inclusions in the pallidus, together with glio-
sis and neuronal loss.63
Symptomatology. The pallidus plays an important role in
response inhibition, reducing thalamocortical output and
consequently the activation in the motor cortex.64,65
Consequently, pallidus atrophy can be associated with
motor perseveration and disinhibition, which are common
symptoms in FTD.66,67 In particular, pallidus atrophy in
these patients has been linked to the ‘applause sign’67
and poor performance at the Go/No-Go Task of inhibi-
tory control.68 In addition, given the role of the ventral
pallidus in the reward processing,69 its degeneration in
FTD correlates with higher reward-seeking behaviours.19
In fact, clinical studies suggested that pallidal lesions can
lead to apathy and anhedonia symptoms,70,71 which are
prevalent across all FTD syndromes,72–74 and emerge
even in presymptomatic mutation carriers.75,76
Other parts of the basal ganglia
Anatomy. The basal ganglia include the substantia nigra
and subthalamic nucleus. The substantia nigra is con-
nected via the subthalamic nucleus to the globus pallidus
in the cortico-striato-pallido-thalamic-cortical circuits, reg-
ulating motor, reward and executive functions.20 The
subthalamic nucleus is also connected to the amygdala,
the orbitofrontal and inferior frontal cortex.77
Neuroimaging. Given the relatively small size of these nu-
clei, there are very few studies looking at volumetric dif-
ferences in the substantia nigra and subthalamic nucleus
in the FTD spectrum, and the main ones are related to
parkinsonian syndromes. One study investigating the iron
content in a cohort of bvFTD and PPA patients failed to
find any difference in the substantia nigra,78 while a post
mortem 7 T MRI study found a significant increase of
iron deposition in the subthalamic nucleus of the FTLD-
FUS, FTLD-TDP-43 and pure ALS groups, but not in the
FTD-tau, while there was no difference in the substantia
nigra from controls.79
Pathology. A case of bvFTD with confirmed TDP-43 type
C showed severe neuronal loss and gliosis without TDP-
43 inclusions in the subthalamic nucleus, while the sub-
stantia nigra was spared.62 FTDP-17 causes mild neuron-
al loss and gliosis of subthalamic nucleus and
depigmentation of the substantia nigra.63 Overall, the
subthalamic nucleus is typically atrophic with gliosis in
the closely related disorder of PSP, while the substantia
nigra shows pallor in most FTLD pathological forms.80
Symptomatology. Nigrostriatal neurons from the substantia
nigra pars compacta regulate the subcortical–cortical
loops for motor, oculomotor and cognitive control,
through their terminations to the striatum.
Neurodegeneration of this structure and reduced level of
dopamine in the substantia nigra is typically associated
with parkinsonian syndromes.81 Parkinsonism with rigid-
ity and akinesia is commonly seen in bvFTD,82 in spor-
adic FTD and especially in FTD arising from mutations
in MAPT, GRN and C9orf72. Specifically, in GRN mu-
tation carriers, the parkinsonism correlates with the de-
generation and neural inclusions in the substantia nigra.83
Pathology in the subthalamic nucleus and its connections
is particularly associated with disinhibition,64,65 but can
also affect emotion recognition and prosody decoding,77
all of which are commonly affected in bvFTD.
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Medial temporal lobe
Hippocampus
Anatomy. The hippocampus is a key component of the
medial temporal lobe, involved in the formation of new
memories and associated with learning and emotion.84,85
Specifically, the posterior hippocampus is involved in
memory processing, through its connections with the
medial and lateral parietal, medial prefrontal and poster-
ior cingulate cortex, via a pathway involving the fornix
projections to the mamillary bodies of the hypothalamus,
anterior thalamic nucleus and anterior cingulate.86,87
The anterior part is instead more involved in emotion
regulation, sensory–motor integration and goal-directed
activity, due to the connections with the limbic structures
(amygdala, nucleus accumbens, ventromedial prefrontal,
orbitofrontal, anterolateral temporal, temporal pole, in-
sula and cingulate cortex).84,86,88,89
The hippocampus is composed of different cytoarchitec-
tonic subfields, mainly part of the allocortex, which have
specialized functions and distinctive connections.85,90
Four main systems have been described87: an episodic
memory network (originating in the subiculum and
involving the anterior dorsal and lateral dorsal thalamic
nuclei, mamillary bodies and retrosplenial cortex); an
emotional–social anterior network (connecting the anter-
ior CA1 and subiculum with the prefrontal cortex, amyg-
dala and nucleus accumbens); a sensory processing and
integration system (connecting CA1 and the subiculum
with the parahippocampal cortex); and a network for
familiarity signalling and retrieval processing, with exten-
sive connection between the hippocampus, the prefrontal
cortex and the thalamus.
The principal efferents of the hippocampus are the
subiculum and CA1, except for the basal forebrain and
nucleus accumbens, which are mainly connected with
CA3.87 Further distinction and indirect pathways have
been identified. The posterior part of the subiculum is
connected to the lateral and medial parietal cortex, the
frontal cortex and the striatum, while CA4 and the den-
tate gyrus are connected with the temporal and posterior
cortex.86,91 The dorsal CA1 and subiculum are connected
to the mamillary bodies and anterior thalamic nuclei, im-
portant for exploratory behaviour and spatial navigation,
while their ventral regions are connected to the amygdala
(central, lateral and basolateral nuclei), basal forebrain,
medial hypothalamus and shell of the nucleus accumbens
to regulate emotions.89 A resting-state functional study91
has found that among the hippocampal regions, CA1
was more strongly connected to the amygdala and occipi-
tal cortex, while CA2, CA3, CA4 and the dentate gyrus
were more strongly connected to the left anterior cingu-
late, temporal and occipital cortex, while the subiculum
to the angular, precuneus, posterior cingulate, frontal cor-
tex and putamen.
Neuroimaging. Hippocampal atrophy has traditionally
been described as particularly characteristic of
Alzheimer’s disease, but many studies over the past
20 years have shown its involvement in some forms of
FTD.9,28,92,93bvFTD have been reported to have 17–23%
smaller hippocampus than controls.7,28,29 svPPA is associ-
ated with a characteristic pattern of asymmetrical atrophy
of the anterior hippocampus (left greater than right), with
usually 25–39% difference from controls on the left and
12–22% on the right92–96; and an annualized rate of at-
rophy of 0.14 on the left and 0.18 ml per year on the
right.97 In contrast, studies generally report no significant
hippocampal atrophy in those with nfvPPA.92
Looking at the genetic forms of FTD, the hippocampus
is particularly atrophic in MAPT mutation carriers com-
pared with C9orf72 and GRN mutation carriers.98–100
Volume loss occurs around 15 years before expected
onset in MAPT mutation carriers,17 with a faster annual
rate of atrophy compared with other genetic forms of
FTD.31,101
In patients with pathologically confirmed FTD, the
hippocampus has been shown to be significantly smaller
in Pick’s disease (33% volume difference from controls)
as well as in FTDP-17 (i.e. MAPT mutations: 43%) and
TDP-43 type C cases (usually those with svPPA: 33%).
Other pathologies have involvement to a lesser extent:
FUS (31%), TDP-43 type A (23%) and CBD (14%).15
Hippocampal subfields have also been investigated in
FTD. In svPPA, both the CA1 and subiculum regions
were significantly smaller in svPPA than controls (27%
and 24% volumetric difference, respectively).96 In a study
of genetic FTD, a differential pattern of involvement was
seen in the different groups: MAPT mutation carriers
showed a 24–27% volumetric difference in the hippocam-
pus proper (formed by the CA subfields), whilst C9orf72
expansion carriers showed most atrophy in the dentate
gyrus and CA1/4 (8–11%), and GRN mutation carriers
were most affected in the subiculum and presubiculum
(10–14%).100 In a larger study looking at different dis-
ease stages,33 all hippocampal regions were smaller than
controls for fully symptomatic carriers for mutations in
all three major genes. Differences were detected in several
regions at asymptomatic and prodromal stages in both
MAPT (the earliest in subiculum, presubiculum and tail)
and C9orf72 groups (the earliest in dentate gyrus, CA1/4
and presubiculum), and in the presubiculum (8%) in the
prodromal stages of GRN mutation carriers.
Pathology. At post mortem, the hippocampus shows mild
to severe neuronal loss, with 48% of cases showing hip-
pocampal sclerosis (typically TDP-43 proteinopathies) and
64% showing the classic ubiquitinated inclusions in the
dentate gyrus.12,102 In cases with confirmed TDP-43
pathology, the head of the hippocampus shows an aver-
age 57% atrophy in svPPA compared with controls,
while bvFTD has 46% atrophy, more evenly distributed
along the hippocampus.103 Pick’s bodies are consistently
found in the granule cells of the dentate gyrus, the pyr-
amidal cells of CA1 and the subiculum,12,13,102 whilst
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tau-positive grains and pre-tangles are found in the CA1
and dentate gyrus.12
Pathological studies in general are consistent with in vivo
imaging of the genetic groups: tau deposition is extensively
found in the hippocampus and other limbic structures in
MAPT mutations104; dipeptide repeat proteins, together
or without TDP-43 deposition, are found in the CA subre-
gions in C9orf72; while TDP-43 accumulates in the
hippocampus and the cortex in GRN.105
Symptomatology. The hippocampus is central to memory.
Although significant episodic memory impairment is an
exclusion criterion under current diagnostic criteria for
bvFTD, improving the distinction from other causes of
dementia, episodic memory can be affected in FTD.
Indeed, several of Pick’s original cases had prominent
memory symptoms, and one study reported amnesia in
the initial clinical evaluation of 10% of pathologically
confirmed cases.106 In bvFTD, memory deficits can co-
occur with executive dysfunction, and involve both retro-
grade and anterograde memory performance. Similarly,
svPPA patients can present episodic memory deficits,
while nfvPPA patients generally show only mild autobio-
graphical memory difficulties.107 Such episodic memory
deficits in both bvFTD and svPPA are attributable in part
to hippocampal dysfunction. Specifically, there is an asso-
ciation in bvFTD between hippocampal degeneration and
deficits in memory recall and storage impairments,47,108
and episodic future thinking deficits.109 Hippocampal
dysfunctions also relate to reduced mind wandering cap-
acity110 and scene construction performance.111 However,
despite the presence of hippocampal degeneration, FTD
patients typically show preserved spatial navigation cap-
acity in contrast to patients with Alzheimer’s disease and
structural hippocampal lesions, suggesting that degener-
ation in the posterior parietal structures and other brain
regions may mediate these deficits.112
Hippocampal deficits are relevant to more than mem-
ory domains in FTD, as this structure is involved in emo-
tion modulation and evaluation of facial emotion.113
These are impaired not only in bvFTD but also in
svPPA, especially right semantic dementia, and ‘temporal
variant’ FTD.114 Atrophy in the anterior hippocampus in
bvFTD and svPPA correlates with the typical symptoms
of these two clinical groups: apathy and impaired social
conduct in bvFTD, and anomia and impaired single word
comprehension with preserved episodic memory in
svPPA.115 Hippocampal volume is also reduced in FTD
patients presenting with obsessive–compulsive behav-
iours.116 There are genetic influences on the hippocampal
pathology and symptomatology. For example, severe
medial temporal atrophy is seen in MAPT mutation car-
riers, with the greater involvement of the anterior and
central regions of the hippocampus which form part of
the limbic system: this is associated with the difficulties
seen in these patients in regulating emotion and goal-
directed behaviour.31
Amygdala
Anatomy. The amygdala is a limbic structure, composed
of several subnuclei with different connections to the rest
of the brain.117,118 The amygdala is involved in motiv-
ation, emotion, reward learning and in other cognitive
functions (attention, perception and explicit memory).117
The nuclei of the amygdala are heterogeneous in com-
position, connections and roles.117 The lateral and basal
amygdala are considered cortical regions, while the cen-
tral and medial nuclei are considered ventral extensions
of the striatum. The lateral nucleus is the ‘gatekeeper’ of
the amygdala, as the major receiver of inputs from sen-
sory and somatosensory systems, and important for proc-
essing of pain, fear learning and memory. The central
nucleus is instead the most important output region, key
for the control of motivation, emotional and behavioural
responses, and connected to the brainstem, striatum, thal-
amus (mediodorsal, pulvinar and central nucleus), basal
forebrain and lateral hypothalamus.117,118 Together with
the central nucleus, the accessory basal, basal and parala-
minar nuclei are considered the main component of the
reward system within the amygdala, to motivate and
reinforce behaviours.117–121
Neuroimaging. Amygdalar atrophy is common in bvFTD
with prior studies reporting a 19–33% volume loss on
the right and 22–41% on the left.122,123 Patients with
svPPA show more atrophy than those with nfvPPA and
bvFTD,14,123 with a strong asymmetry: 51–65% volume
difference on the left (when left-predominant svPPA),
and 33–54% on the right amygdala when compared to
controls.9,94,95,97,123 Volume loss is smaller in bvFTD,
around 10–19% smaller than controls in one study, with
an annual atrophy rate of 4%.7,27,28
Studies of genetic FTD have shown that the amygdala
is particularly affected in MAPT mutation carriers,31,99 a
decade or more before the symptom onset.17 With recent
developments in imaging technology, the amygdalar sub-
nuclei are now measurable on MR imaging.124
Symptomatic MAPT mutation carriers showed smaller
volumes particularly in the superficial and accessory basal
regions (44%), which were 2–4% smaller even at an
asymptomatic stage.33 Whilst GRN mutation carriers
only showed smaller volumes than controls when fully
symptomatic, C9orf72 expansion carriers showed reduced
volumes in all amygdalar regions even at the asymptom-
atic and prodromal stages, with the main reduction being
in superior-medial regions.33
In pathologically confirmed cohorts, amygdalar atrophy
is most marked in cases with FTDP-17 (MAPT mutation
carriers) and TDP-43 type C (usually svPPA),15,125,126
with 50% smaller volume than controls.15 When looking
at the evolution of brain atrophy in svPPA with and
without confirmed TDP-43 type C pathology, the amyg-
dala was found to be affected at the very early stages
on both sides.37,126,127 However, there is also significant
involvement in those with Pick’s disease (45% difference
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from controls), more so than those with FUS (37%),
TDP-43 type A (25%) or CBD (20%) pathology.15,126
For the amygdalar subregions, a recent study of patho-
logically confirmed FTD cases reported a differential in-
volvement with the medial subnuclei (particularly the
superficial, accessory basal and basal/paralaminar subnu-
clei) being more affected than the lateral subnuclei.126
Pathology. Neuropathological studies have shown severe
amygdalar volume loss of 52% in FTD.128 One study on
TDP-43 pathology showed inclusions in the basolateral
nucleus of the amygdala in the earliest stage of the
disease.129
Symptomatology. Amygdala is a key area in the reward
and punishment system. The core behavioural features
and symptoms of FTD (i.e. lack of insight, impaired per-
sonal and social conduct, disinhibition) are consistent
with the loss of function of the amygdala, and are regu-
larly seen with all types of FTD-related pathology.12,13
The subnuclei most affected in FTD are connected to other
limbic regions. Across all FTD variants, atrophy of the
amygdalar subnuclei relates to a wide range of behavioural
and neuropsychiatric scales,14 either directly or through the
deficits in the reward and emotional processing caused by
bvFTD and svPPA.130,131 The medial nuclei are likely
related to the development of symptoms associated with
abnormal reward and emotional processing, relative to the
salience and limbic networks132,133: indeed the amygdala
plays a role in evaluating the motivation and emotional
context of a given stimulus, and feedbacks the information
to the brainstem to control emotional reaction, and to the
striatum to control actions.117
Atrophy and hypometabolism of the amygdala relate to
deficits in the emotion processing and recognition, and
social interaction insight.134–138 It is also linked to
impaired comprehension of intentionality,139 and insensi-
tivity to negative stimuli.140 Some reports indicate right
sided associations134,135,137,138 while others reveal left
sided associations,137,141 especially involving the superfi-
cial and basolateral nuclei. Deficits in social cognition, in-
teroceptive accuracy or emotion comprehension were
found to be related to amygdalar atrophy on the right
hemisphere or bilaterally in svPPA138,142 and the tem-
poral variant of FTD.114 In patients with the ‘right tem-
poral variant of FTD’, deficits in facial expression
recognition, reduced empathy and emotional reaction are
commonly observed.114 Emotion recognition deficits
correlate with atrophy in the left amygdala in patients
with nfvPPA.143
Basal forebrain
Anatomy. The basal forebrain is a collection of cholinergic
nuclei, including the diagonal band of Broca, the medial
septal nucleus and the nucleus basalis of Meynert.144 Via
cholinergic pathways linking the cortex and limbic sys-
tem, they are essential for different cognitive processes,
including memory, learning and attention.145,146
Neuroimaging. Basal forebrain volume is reduced in both
svPPA and nfvPPA as compared to controls, mainly in
the posterior part of the nucleus basalis.147–149 Patients
with bvFTD and svPPA were reported to have significant-
ly lower volumes than controls (9–10%) and nfvPPA
(4–5%), with FTD-ALS and all PPA variants also having
lower volumes than controls (5–9%).150 Among genetic
cases, only fully symptomatic MAPT mutation carriers
showed significantly smaller basal forebrain volumes
than controls (15–18%) and both GRN and C9orf72
groups (14–17%).33,150 In the same study,150 pathologic-
ally confirmed cases with tau showed the smallest basal
forebrain volumes (mainly driven by FTDP-17 and Pick’s
disease) than controls (10%), while among the TDP-43
proteinopathies, the lower volumes were driven by those
with TDP-43 type C pathology.
Pathology. In one study, TDP-43 inclusions have been
found in the basal forebrain (including the diagonal band
of Broca, nucleus basalis of Meynert and substantia inno-
minata).44 Patients with PPA showed a severe reduction
in the cholinergic neurons in the nucleus basalis of
Meynert and nucleus subputaminalis.151
Symptomatology. Atrophy and pathology of the basal fore-
brain can lead to diverse symptoms in FTD, but a unify-
ing framework for these effects is outstanding. The
cholinergic system plays a key role in cognitive process-
ing, and the cholinergic dysfunction seen in bvFTD and
PPA arise from the degeneration of the nucleus basalis.
For example, language impairment in PPA has been par-
tially attributed to the cholinergic deficits from the basal
forebrain pathology.147,148,152,153 A role of the basal fore-
brain in social cognition and attachment has been pro-
posed, given the density of receptors for oxytocin and
vasopressin.154 This accords with the association between
basal forebrain hypometabolism with abnormal prosocial
sentiments in bvFTD (i.e. pity and guilt).155 Despite these
associations, cholinergic dysfunction seems to be more
marked in CBS and PSP than other FTD syndromes,
which may in part explain why cholinesterase inhibitors
have not proven effective to improve cognitive function




Anatomy. The thalamus is the relay station of the brain,
and it is connected to the majority of other regions. It is
composed of several nuclei, each of them with specific
connections and functional specialization.158 While the
anterior, lateral, ventro-anterior and medio-dorsal nuclei are
considered limbic structures, the ventrolateral and ventro-
medial are considered motor, and the latero-posterior,
ventro-posterior lateral, midline and intralaminar are consid-
ered associative and somatosensory (reviewed in Bocchetta
et al.159). The lateral and medial geniculate nuclei have
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specific sensory functions in the visual and auditory system,
while the pulvinar plays a role in the intramodality integra-
tion of somatosensory and visual information, and in the
presence of affective and psychotic symptoms, including
hallucinations.
Neuroimaging. Thalamic atrophy is a common feature
across all clinical, genetic and pathological forms of
FTD,17,160–162 and occurs even in the early clinical
stages.8 bvFTD and nfvPPA show bilateral atrophy in the
anterior and posterior thalamus.14,16,28 Both Pick’s
disease and TDP-43 type A groups showed asymmetric
volume loss in the thalamus.15
Among the genetic groups, the C9orf72 expansion carriers
have been considered to be the ones where the thalamus
was particularly affected, even presymptomatically17,163
when considering either those between 20 and 40 years of
age164 or those without any clinical symptoms.33 However,
whilst there is more widespread involvement of the thalamus
later, it seems that the earliest change is in the pulvinar nu-
cleus,165–167 even at a presymptomatic stage168; this region
tends to be less affected in all other forms of FTD.159 In a
detailed study of thalamic subnuclei, the medial dorsal was
affected across all clinical, genetic and pathological FTD
subgroups.159 Changes in the thalamic regions only become
visible at the fully symptomatic stages in both GRN and
MAPT mutation carriers, with atrophy mainly localized in
the medial dorsal, midline and laterodorsal nuclei (22–
31%), while the lateral geniculate nucleus was spared in
both groups, but atrophic in C9orf72.33
Pathology. Post mortem volume analysis of svPPA con-
firmed 27% loss of volume in the anterior thalamus103
and 34% reduction for bvFTD, with confirmed TDP-
43 pathology. From a subnuclei point of view, patho-
logical studies have shown a marked involvement of
the medial dorsal nucleus, with neuronal loss, gliosis
and astrocytosis in bvFTD.169 However, pathological
hallmarks of FTD are not evenly distributed in the
thalamus. For example, TDP-43 is mainly found in the
medial nuclei of thalamus (including anterior, lateral
dorsal and dorsomedial nuclei), in the periventricular
thalamic neurons, while few inclusions are found in the
lateral nuclei of the thalamus.44
Symptomatology. The heterogeneity of thalamic nuclei and
their position within parallel cortico-striato-thalamo-cor-
tical loops for cognition and motor control means that
the thalamic pathology in FTD gives rise to diverse symp-
toms and signs. However, there is ongoing work looking
at the specificity of the thalamic origin of the FTD symp-
toms, trying to accurately localize the thalamic nucleus
involved for each clinical phenotypes and genetic forms.
It is also challenging to dissociate the direct effects of
pathology of the thalamic nuclei, from changes in their
afferent and efferent connections,19 and degeneration of
the cortical projections of each nucleus.
The symptomatology of thalamic changes in FTD fol-
lows the functional anatomical circuits discussed above.
For example, in C9orf72 expansion carriers the pulvinar
pathology is consistent with impairment of limbic
functions and intramodality integration of sensory informa-
tion,158 including altered processing of pain, hallucinations,
affective and psychotic manifestations of FTD.170–172 In
bvFTD, atrophy in the pulvinar also relates to lower
prosocial giving,173 consistent with an integrative role in
social, affective and reward processing. In contrast, path-
ology in the medial dorsal nucleus in different variants of
FTD affects connectivity with widespread brain regions
including orbital, lateral and dorsal prefrontal cortex, and
other limbic regions. This can exacerbate emotional and
executive impairments over and above the cortical path-
ology. Damage in the thalamic regions forming part of the
anterior cingulate circuits have been associated with
changes in apathy and memory.169 As part of the Papez
circuit, thalamic degeneration may increase memory
deficits, where for example atrophy in the thalamus and
fornix has been reported to be associated with severity of
amnesia in bvFTD.162
Hypothalamus
Anatomy. The hypothalamus plays an important role in
food intake, reward and perception of satiety. It also reg-
ulates the homeostasis of neuroendocrine, behavioural,
and autonomic processes, including circadian rhythm,
stress response, sexual and defensive behaviours and
thermoregulation.174,175 It is composed of a number of
different subnuclei and is highly interconnected with
other parts of the central nervous system, particularly the
brainstem, limbic system and cortex. Besides axonal
connections, the hypothalamus contains neuropeptide-
expressing neurons and neuropeptide receptors, and it
engages with the pituitary gland to release hormones into
the bloodstream.175,176 The nuclei involved in the food
intake are mainly the lateral hypothalamus, and the arcu-
ate, dorsomedial and paraventricular nuclei.175
Neuroimaging. In a study of eighteen people with bvFTD,
hypothalamic volume was reduced 17% compared with
controls, with the main differences localized to the super-
ior parts of the anterior and tuberal regions and the pos-
terior region, which regulate appetite.177 Another study
has confirmed atrophy of the hypothalamus in bvFTD,
particularly in its posterior portion, but not in svPPA.178
In a small study which included those with genetic
FTD, atrophy was significantly more severe than controls
in MAPT mutation carriers (in superior and posterior
areas), but not in those with C9orf72 expansions. In par-
ticular, the posterior part of the hypothalamus was the
most affected area, including the mamillary bodies, which
are connected to the amygdala and hippocampus, both
structures known to be particularly atrophic in MAPT
mutation carriers.177 In a larger study across disease
stages,33 hypothalamic volumes were smaller in fully
symptomatic mutation carriers (except for the inferior tubu-
lar regions in C9orf72 and GRN), with MAPT symptomatic
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carriers showing up to 29% smaller volumes in the poster-
ior and anterior regions. However, the only group showing
smaller volumes before symptom onset was C9orf72,
especially in the superior anterior and tuberal regions.
Pathology. Multiple pathologies have shown involvement
of the hypothalamus. For example, one study showed a
volume reduction of 41% in bvFTD and TDP-43 path-
ology cases when compared to controls.103 In a post
mortem study of 19 cases with TDP-43 pathology, inclu-
sions were found in the lateral hypothalamic area, tuber-
omammillary nucleus, lateral tuberal nucleus, preoptic
area, ventromedial and dorsomedial nuclear groups, and
in the posterior hypothalamic area. No inclusions were
seen in other hypothalamic regions.44 The hypothalamic
lateral tuberal nucleus was also shown to be severely
affected in Pick’s disease.12 Cases with tau pathology and
Pick’s disease showed more abnormal protein deposition
than cases with TDP-43 type B, with this latter showing
more severe posterior hypothalamic atrophy than the tau
group.179
Symptomatology. The key role of the hypothalamus in
appetite, food-reward and the perception of satiety is
reflected in the symptoms associated with its degeneration
in FTD. Abnormal eating behaviours are present in up to
60% of patients with FTD, and particularly prominent in
patients with bvFTD and svPPA.180 Hyper-orality and
sweet tooth are diagnostic criteria for bvFTD,1 but the
specific symptoms vary widely between individuals.
bvFTD can present with complex eating behaviours, from
overeating to sweet craving, to obsessions for specific
foods.181 Alteration in eating behaviours may be driven
by hypothalamic pathology via multiple processes, over
and above cortical and striatal mediation of poor impulse
control and environmental dependency. Posterior and
whole hypothalamic atrophy has been shown to correlate
with abnormal eating behaviours.178,182 Specifically, feed-
ing behaviour alterations are related to localized degener-
ation in the lateral hypothalamic nuclei, and the arcuate
and paraventricular nuclei.183 In contrast, lesions in pos-
terior hypothalamus contribute to autonomic dysfunction
and altered satiety responses.184
Structural and functional alterations of the hypothal-
amus are associated with autonomic deficits in bvFTD,
such as lower baseline skin conductance levels.185
Cardiac, urinary and thermoregulatory dysfunctions have
been reported in patients with FTD,186,187 as described in
the original diagnostic criteria.188 Sleep disturbances are
also prevalent in FTD,189 and might be associated with
hypothalamic degeneration and the loss of its connections
with the frontotemporal cortex.190 The direct sleep distur-
bances from FTD need to be separated from indirect
effects of physical disability, motor deficits, poor sleep
hygiene arising from altered lifestyle, and iatrogenic
pharmacological impairments. Nonetheless, sleep disturb-
ance as a result of FTD itself is common, including either
hypersomnolence or insomnia. These can be refractory to
treatment, arising from degeneration of central thalamic
or hypothalamic regulators of circadian rhythms.
Habenula
Anatomy. The habenula is a small but key nucleus within
the reward network.191 It integrates information from the
other limbic structures and basal ganglia to generate
goal-directed behaviours, by processing and balancing re-
ward and adversity.192,193 The lateral habenula is con-
nected to the lateral hypothalamic and lateral preoptic
areas, basal forebrain, ventral pallidus, amygdala, sub-
stantia nigra and brainstem.192 It also receives input from
the anterior insula, anterior cingulate and ventral frontal
pole.193 The medial habenula is connected to the basal
forebrain and midbrain.193
Neuroimaging. Only one small study has reported the
habenula changes in FTD, showing a 29% lower volume in
bvFTD compared with controls.194 Other studies have not
reported this structure in FTD, perhaps due to its small size
and the lack of an automated method which currently
makes its quantification unfeasible in large cohorts.
Pathology. There are currently no studies reporting the
presence of pathology or neurodegeneration in the habe-
nula in FTD.
Symptomatology. The habenula mediates the processing of
negative and aversive information, and suppresses actions
when it is anticipated that these will not produce a re-
ward or avoid a negative feedback.193,195 The habenula
is activated by negative feedback.196 Given this function,
neurodegeneration in the habenula can lead to persever-
ation (due to inconsistence use of negative feedback) or
disinhibition and impulsivity (due to inability to avoid an
action),192 and to the abnormal reward behaviours often
seen in bvFTD patients. In addition, in animal studies,
the lateral habenula and its connections with prefrontal
regions have been reported as implicated in working
memory and other executive functions,197–199 which are
characteristically impaired in patients with bvFTD.1 The
role of habenula in these functions is also supported by
its modulatory role on the activity of the dopaminergic
system.200,201 However, further work is required to estab-
lish the specific role of habenula dysfunction as a direct
cause of behavioural change in FTD.
Brainstem and cerebellum
Brainstem
Anatomy. The brainstem is divided into the midbrain,
pons and medulla oblongata. The midbrain is associated
with vision, hearing, sleep and motor control, and it also
forms part of a network that regulates emotion perception
with the thalamus and amygdala.202 The pons is connected
to both the cerebrum and the cerebellum, via the cerebellar
peduncles, and it is associated with respiration and facial
expression. The medulla connects the cerebrum to the spi-
nal cord, and regulates cardiac and respiratory functions,
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reflexes and integrative functions, such as consciousness,
emotional processing, pain and motivation.203
Neuroimaging. Few imaging studies have focussed on the
brainstem in FTD, perhaps because of the exclusion of
the brainstem from early imaging atlases of grey matter.
However, brainstem changes are typical of other tauopa-
thies, and in particular CBS and PSP, with PSP showing
marked atrophy in the midbrain and superior cerebellar
peduncle.204–206 As PSP often overlaps clinically with
nfvPPA and bvFTD,3,207 it is not surprising that patients
with these overlapping syndromes present with brainstem
involvement in addition to the typical cortical pattern of
bvFTD and PPA.208 A study of 22 FTLD patients (5 of
whom also met criteria for ALS) reported 10% smaller
volumes than controls in the brainstem, including mid-
brain, pontine tegmentum, superior and inferior colli-
culi.161 In a diffusion imaging study, bvFTD, bvFTD
with ALS, nfvPPA, and PSP patients showed abnormal
measures in the brainstem, while in svPPA the brainstem
was spared.209 This also suggested that patients with
probable tau pathology (like nfvPPA and PSP) showed
abnormal changes in the brainstem, superior and inferior
cerebellar peduncles more than those with probable TDP-
43 pathology (svPPA and bvFTD with ALS). However,
the brainstem, and specifically the pons, has been found
to be atrophic in GRN mutation carriers, who typically
show TDP-43 pathology.31 This result was confirmed by
a recent large study on genetic FTD,33 which reported 5–
8% smaller volumes of the superior cerebellar peduncle,
midbrain and pons in GRN mutation carriers, 9%
smaller midbrain volumes in MAPT mutation carriers,
but no difference in C9orf72 expansion carriers, nor in
any presymptomatic carriers.
Pathology. TDP-43 pathology and neuronal loss has been
found previously in several nuclei of the midbrain and
pons in cases with bvFTD, bvFTD and ALS, and PPA
variants.210,211
Symptomatology. Despite the name ‘frontotemporal de-
mentia’, brainstem pathology is commonly associated
with functional impairment in FTD. Functional networks
responding to salient events and enabling adaptive behav-
iour include brainstem nuclei, and they are impaired in
FTD.212 The salience network is active in response to
stimuli that are emotionally significant.132 In this way,
brainstem degeneration contributes to some of the deficits
in social cognition and emotion processing attributed to
cortical pathology in FTD. In addition, the thalamus–
amygdala axis for emotion and social perception is mod-
erated by brainstem projections,202 and especially by the
midbrain, which is affected in MAPT mutation carriers.
The brainstem reticular activating system and its projec-
tions to the cerebrum are critical for arousal, and its neu-
rodegeneration is associated with apathy in FTD.74
Beyond behavioural symptoms, the clinical overlap be-
tween FTD, PSP and other forms of parkinsonism also
consists in motor symptoms, which are underpinned by
brainstem degeneration, as identified by post mortem and
imaging studies.74,82,207 These symptoms include impair-
ment of oculomotor control by the superior colliculus in
the midbrain tectum.213 Atrophy of the tectum occurs in
FTD,161 explaining saccade abnormalities in these
patients with and without PSP-aetiology.214 In particular,
in PSP this manifests in slow and hypometric vertical sac-
cades, and later a vertical gaze palsy.
Brainstem nuclei are the main sources of the principal
modulatory neurotransmitter systems, including serotoner-
gic, dopaminergic and noradrenergic innervation of the
forebrain. FTD affects the serotonergic projections from
the raphe nuclei, the dopaminergic projections from the
ventral tegmental area and the noradrenergic projections
from the locus coeruleus.81 Changes to such fundamental
distributed systems are expected to have widespread con-
sequences on cognition and behaviour. Indeed, serotonin
dysfunction in FTD is confirmed by reduced transmission
and postsynaptic receptor density, and relates to behav-
ioural changes, such as aggression, impulsivity and
increased appetite.215–216 In many patients, FTD is associ-
ated with depletion of nigrostriatal dopamine projections,
loss of pre-synaptic dopaminergic neurons and altered
dopamine receptor binding in the striatum. This leads to
cognitive change, motor parkinsonism and vulnerability
to iatrogenic extra-pyramidal symptoms.82,217 Impairment
in the noradrenergic system from degeneration in the
locus coeruleus is likely to contribute to the dysregulation
of attention, memory and decision-making, although spe-
cific associations in FTD are yet to be established as they
have been for PSP.218–220
Cerebellum
Anatomy. Traditionally, cerebellar function has been asso-
ciated only with the coordination of movement, but re-
cent studies have found that the cerebellum is important
in cognitive and emotional processing.221,222 The cerebel-
lum has several connections with key areas involved in
FTD, in particular to the prefrontal cortex via the thal-
amus,223,224 and to the limbic system via a direct cere-
bello-limbic pathway.225–227 More specifically, the
superior–posterior cortex (lobule VI, VIIa-Crus I, VIIa-
Crus II, VIIIb), connected to the ventrolateral and ventro-
anterior thalamus to the prefrontal cortex, has been asso-
ciated with cognitive processing (executive functions, lan-
guage, attention) and social cognition.221,222,224 The
vermis is instead also called the ‘limbic cerebellum’, as it
plays a role in the modulation of emotional and social
behaviours.221,225–227 The anterior cerebellum is instead
the area linked with motor/sensorimotor functions.221
The deep cerebellar nuclei (dentate, interposed and fasti-
gial nuclei) receive intrinsic inputs from the cerebellar
cortex to be sent to the other cortical regions via the ven-
tro-anterior and ventrolateral thalamic nuclei.221
Neuroimaging. Differential involvement of the cerebellum
has been shown in FTD, as also highlighted in a recent
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metanalysis of neuroimaging studies.228 Overall, in
bvFTD changes were found in the Crus bilaterally, in the
left lobule VI, in the right lobules VIIb and VIIIb, and
part of the vermis.229,230 In svPPA, changes were asym-
metric, and mainly located in the left Crus I and lobule
VI,228 but also in the left lobules IV–V.229 Cerebellar at-
rophy was also observed in nfvPPA, localized bilaterally
in the lobules VI, right Crus I and VIIb.229,230
The involvement of the cerebellum in C9orf72 expansion
carriers has been well characterized,17,99,231,232 with the lob-
ule VIIa-Crus I and VIIa-Crus II in the superior–posterior
region of the cerebellum particularly involved, even at the
earliest presymptomatic stages.33,233 A small cohort of
symptomatic mutation carriers233 found the cerebellum to
be relatively spared in those with GRN mutations, and
localized to the vermis in MAPT mutation carriers, the ‘lim-
bic cerebellum’ involved in the modulation of emotions and
social behaviours, as already mentioned.221,225 However, a
larger cohort using the same methods did not confirm such
differences in the MAPT group, but reported 8–13%
smaller volumes in lobules VIIa-Crus II, VIIb and VIIIa in
fully symptomatic GRN mutation carriers.33
Pathology. Interestingly, dipeptide repeat proteins, the
characteristic pathology of C9orf72 expansion carriers,
are found throughout the cerebellum, in case with or
without ALS phenotype.5,232,234–236 Post mortem examin-
ation of two siblings with bvFTD showed massive abnor-
mal tau deposition in astrocytes in the cerebellum.237
Symptomatology. The cerebellum has long been associated
with motor control, and its lesions with ataxia. Although
uncommon, ataxia has been described in patients with
C9orf72 expansions.238,239
Beyond motor control and movement, cerebellar func-
tions extend to all areas of cognition, including affective,
social and executive domains. Its role in cognitive and
emotional processing in FTD is now emerging. For ex-
ample, in bvFTD, Tan et al.240 found an association be-
tween lobules V and VII (Crus I) and memory, language,
executive and emotion deficits, together with an associ-
ation between the vermis and memory and language dys-
function. Areas of cerebellar atrophy were linked with
attention and working memory in bvFTD, visuospatial
function in svPPA, and language-motor function in
nfvPPA.230 Atrophy in the Crus and lobule VI was com-
monly associated with cognitive deficits in all FTD phe-
notypes, and in the Crus I and Crus II were associated
with both behavioural disruption and cognitive
dysfunctions.228
Changes in cerebellar connections have been linked
with loss of episodic memory, attention, working mem-
ory, visuospatial, executive function and emotion in
bvFTD; with working memory, language and emotion in
svPPA; and with attention, language, executive function,
working memory, visuospatial and emotion in nfvPPA.241
Altered emotion processing and motivation have been
described in patients with cerebellar damage,240,242,243
and found related to cerebellar degeneration and discon-
nection in all FTD variants.240,241 Cerebellar degeneration
also correlates with eating behaviours in both bvFTD
and svPPA,244 and with decision making and theory of
mind in bvFTD.245–247 In C9orf72, structural changes in
the cerebello-thalamic-cortical network are seen early pre-
symptomatically, and by the time C9orf72 expansion car-
riers reach the symptomatic stage, they have disturbances
of body schema and related neuropsychiatric symptoms
related to cerebellar disease.248
Conclusion
Existing studies reveal extensive involvement of subcor-
tical structures in the clinical, genetic and pathological
forms of FTD. As summarized in Fig. 2, there is a com-
plex differential pattern of atrophy in the different struc-
tures across the FTD spectrum. In general, bvFTD is
associated with multiple regions of the reward network,
including the nucleus accumbens, amygdala, hypothal-
amus and habenula. More specifically, by genetic and
pathological group, the limbic structures (such as the
amygdala, the hypothalamus, the posterior hypothalamus
and the nucleus accumbens) are mainly affected in those
with MAPT mutations as well as Pick’s disease, while the
basal ganglia are mainly involved in those with GRN
mutations and FUS pathology. C9orf72 expansion car-
riers have a particular involvement in the pulvinar nu-
cleus of the thalamus and the cerebellum, forming part of
a cerebello-thalamic-cortical network related to neuro-
psychiatric symptoms in this group. Further studies are
needed to explore and fully understand the role of these
nuclei in all the forms of FTD, and in particular how
their place within wider networks is lost as connections
are broken down with disease progression.
The studies included in this review differ in a number
of characteristics, including the imaging techniques used
(manual or automated segmentation, volumetric region of
interest or voxel-based morphometry), the sample size,
the inclusion criteria for patients, the quality of MR
images and the covariates included in the comparisons
(disease duration, severity of symptoms, global atrophy).
Therefore, results are not always directly comparable, or
amenable to meta-analysis. Collaborative studies investi-
gating multiple structures at the same time on large
cohorts will be better able to provide a clearer picture of
subcortical changes in FTD, including disease progression
and variants. Adequately powered longitudinal studies,
including sample size estimates, are essential to under-
stand the variability of subcortical structures, especially
small but critical structures, such as the habenula and
subthalamic nucleus. These are difficult to identify using
automated methods or from clinical-grade images. The
anatomical definition of the boundaries of some of these
structures is also a relevant source of heterogeneity, not
only across neuroimaging studies, but also post mortem
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investigations. Initiatives like the harmonization of hippo-
campal subfields (www.hippocampalsubfields.com
Accessed on 21 July 2021)249 are underway and will pro-
vide relevant resources to accurately address sources of
variability. These investigations will be fundamental to
develop MRI markers that include subcortical regions
that are reproducible across studies, and for single subject
assessments for stratification and monitoring in clinical
trials.
With this review, we draw attention to the important
role that the subcortical structures play in the spectrum of
FTD, which has often been overlooked in the past. These
regions are affected differently across the FTD disorders,
and show clear early changes in the disease process.
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213. Rüb U, Heinsen H, Brunt ER, et al. The human premotor oculo-
motor brainstem system - can it help to understand oculomotor
symptoms in Huntington’s disease? Neuropathol Appl
Neurobiol. 2009;35(1):4–15.
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